GlassScriptPhysician profile
Asif Alavi
NPI 1790952562
$17,344.00
in general payments reported to CMS, 2019-2025
11 companies · $3,218 in 2025
The $3,218 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,842 · 2023: $9,284 · 2025: $3,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,625 · Travel and Lodging: $2,467 · Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,625.00 |
| Travel and Lodging | $2,467.16 |
| Food and Beverage | $409.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $9,312.60 | 2023-2025 | |
| Genzyme Corporation | $3,424.70 | 2021 | |
| Agios Pharmaceuticals, INC. | $1,693.74 | 2025 | Pyrukynd |
| Terumo Bct, INC. | $1,495.46 | 2025 | Spectra Optia |
| Sanofi-Aventis U.S. LLC | $1,417.50 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Alavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.